EMBL partners with the Hungarian Centre of Excellence for Molecular Medicine
EMBL has recently formed an inter-institutional collaboration with the Hungarian Centre of Excellence for Molecular Medicine (HCEMM), setting the stage for the ongoing transfer of institutional, research and collaborative expertise between the two organisations. Researchers at HCEMM will also have access to the EMBL Partnership network across Europe and further afield.
HCEMM is a newly established non-profit organisation, researching the diagnosis and treatment of cancer, cardiovascular and inflammatory diseases. It will bridge the gap between fundamental and translational research by undertaking projects with relatively rapid clinical applications. Following EMBL’s model, HCEMM aims to provide scientific autonomy, transparent policies, financial stability and modern infrastructure for talented scientists. The goal of HCEMM is to become an internationally recognised centre of excellence in molecular medicine. To achieve this, researchers at HCEMM will have access to advanced core facilities, effective processes for technology transfer and active links to industry.
HCEMM was financed, in part, by a Horizon 2020 Teaming grant. The Teaming initiative partners leading European institutions with other institutions or regions that are less established in the fields of research and innovation, with the aim of creating new centres of excellence across the continent.
The nucleus of this cell fluoresces in bright green thanks to GFP-labelled nucleoporin proteins. EMBL scientists use engineered nucleoporins as 3D reference standards to improve super-resolution microscopy.